ReviewFrontiers in immunology2026
Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the expanding identification of target antigens in primary membranous nephropathy (PMN), treatment is shifting from empirical immunosuppression toward mechanism-based precision immunotherapy. Although rituximab (RTX) has substantially improved the management of PMN, a considerable proportion of patients still experience suboptimal response, relapse, or resistance. Accumulating evidence indicates that RTX resistance is a multifactorial process involving anti-drug antibody formation, reduced bioavailability, incomplete depletion of pathogenic B cells within lymphoid compartments, CD20 internalization and degradation, epitope spreading, persistence of autoantibodies against intracellular antigens, and genetic susceptibility. In response, a broad range of mechanism-guided therapeutic strategies is emerging, including next-generation anti-CD20 monoclonal antibodies, agents targeting distinct stages of B-cell differentiation, and advanced immune-engineering approaches such as CAR-T, CAAR-T, CAAR-NK, CAR-Treg, CAR-macrophage therapies, sweeping antibodies, antibody-drug conjugates, and bispecific autoantigen-T-cell engagers. In parallel, interventions targeting aberrant T-B cell crosstalk and complement activation are providing additional therapeutic opportunities for refractory disease. This review systematically summarizes the major pathogenic mechanisms underlying RTX-resistant PMN and integrates the latest advances in mechanism-based therapeutic strategies, with the aim of informing individualized treatment approaches and future translational research for refractory PMN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.